2805 T3D2763 Anidulafungin Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. 166663-25-8 166548 C58H73N7O17 1139.506290 White powder. Practically insoluble Injection Anidulafungin is a semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-&beta;-D-glucan, an essential component of the fungal cell wall, ultimately leading to osmotic instability and cell death. Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 (CYP450) isoenzymes. Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity. Route of Elimination: Less than 1% of the administered radioactive dose was excreted in the urine. Anidulafungin is not hepatically metabolized. Half Life: 40-50 hours During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day). No indication of carcinogenicity to humans (not listed by IARC). For use in the treatment of the following fungal infections: Candidemia and other forms of <i>Candida</i> infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis. Possible side effects include allergic reaction; bronchospasm; fever, chills, body aches, flu symptoms, sores in mouth and throat; nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); low potassium; hot flashes; diarrhea or constipation; nausea, vomiting. (L1712) During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day). 2009-07-21T20:26:41Z 2026-03-27T01:47:27Z Anidulafungin 55346 Anidulafungin DB00362 true [H][C@@]12C[C@@H](O)CN1C(=O)[C@@]([H])(NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@]([H])(NC(=O)[C@@]([H])(NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O)NC(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O C58H73N7O17 InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 1140.2369 1139.506293945 Exogenous Solid 2.9 HMDB14506 CHEMBL264241 145752 <p>Scott Jenkins, Gary Liversidge, Deborah Neville, &#8220;Nanoparticulate Anidulafungin Compositions and Methods for Making the Same.&#8221; U.S. Patent US20090238867, issued September 24, 2009.</p> CHEM002180 DTXSID50873201 NS00007722 377.41999999999985 292.29319999999984 122.37763185616006 14 17 14 9.457179266012721 -3.484584020108345 0 7 1.87 -4.31 5.64e-02 g/l